Crocetti Daniele, Sapienza Paolo, Cisano Claudio, Tarallo Mariarita, Polistena Andrea, Venturini Luigi, Pedullà Giuseppe, De Toma Giorgio
Department of Surgery "Pietro Valdoni", Sapienza University of Rome, Rome, Italy -
Minerva Chir. 2016 Oct;71(5):281-5. Epub 2016 Jun 29.
We reported our experience with high-risk, non-metastatic second portion duodenal gastrointestinal stromal tumor (GIST)s in patients who underwent 1-month neoadjuvant cycles with imatinib therapy followed by pancreas-preserving surgery and 12-month of adjuvant chemotherapic regimen including imatinib. This study was conducted to evaluate the short and long-term results.
The study was conducted between January 2010 and May 2015. Medical charts and operative logbooks of patients were retrospectively reviewed.
Nine patients form the basis of the current analysis. All patients underwent curative resection with pancreas preservation, and all specimens had histologically negative margins. The median follow-up was 35 months. Eight patients were alive, 1 patient died for myocardial infarction at a mean follow-up of 10 months, 1 patient had a recurrence at a mean follow-up of 32 months and no patients developed distant metastases.
We are confident to suggest the use of neoadjuvant and adjuvant Imatinib therapy to those patients affected with D2, high-risk, duodenal GISTs to allow a limited resection.
我们报告了高危、非转移性十二指肠第二段胃肠道间质瘤（GIST）患者的治疗经验，这些患者接受了为期1个月的伊马替尼新辅助治疗周期，随后进行了保留胰腺的手术，并接受了包括伊马替尼在内的为期12个月的辅助化疗方案。本研究旨在评估短期和长期结果。
该研究于2010年1月至2015年5月进行。对患者的病历和手术记录进行了回顾性分析。
9名患者构成了当前分析的基础。所有患者均接受了保留胰腺的根治性切除术，所有标本的组织学切缘均为阴性。中位随访时间为35个月。8名患者存活，1名患者在平均随访10个月时死于心肌梗死，1名患者在平均随访32个月时复发，无患者发生远处转移。
我们有信心建议对那些患有D2高危十二指肠GIST的患者使用新辅助和辅助伊马替尼治疗，以实现有限切除。
